XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.25.2

CONCENTRATIONS | 3 Months Ended
--- | ---
Mar. 31, 2025
CONCENTRATIONS |
CONCENTRATIONS | (13) CONCENTRATIONS For the three months ended March 31, 2025, the Company sourced approximately 68% of the supplies for its electrotherapy products from four significant vendors. For the same period in 2024, the Company sourced approximately 29% of the supplies for its electrotherapy products from two significant vendors. Significant vendors provided at least 10% of the total value spent on the Company’s electrotherapy products during the period. At March 31, 2025 and December 31, 2024 the Company had no gross receivables from any third-party payers that made up over 10% of the net accounts receivable balance.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration